Moderna’s mRNA-4359, when used with Keytruda, achieves a 24% overall objective response rate in patients with melanoma, with ...

Only men with prostate tumors of the luminal B subtype benefited from adding apalutamide to salvage radiation in the phase 2 ...

In September 2025, the U.S. Food and Drug Administration (FDA) approved several new cancer therapies and supportive care ...

PHILADELPHIA, PA & SAN FRANCISCO, CA — Dispatch Bio announced that it will present new data on its investigational cancer therapy, DISP-10, at the upcoming Society for Immunotherapy of Cancer ...

The U.S. Food and Drug Administration on Friday approved labeling changes for Johnson & Johnson and its partner Legend ...

In psoriasis, like cancers, disease control that includes the well-being of a patient is an additional useful measure of ...

A Bay Area biotech company is on the cusp of a potential breakthrough in blood cancer treatment, with regulators set to make ...

Shares of Nuvation Bio climbed after the company said it has enrolled the first patient in a Phase 3 study for a treatment for early-stage non-small cell lung cancer. The stock rose 13% to $3.64 on ...

CAN-2409 improved disease-free survival in patients with intermediate-to-high-risk, localized prostate cancer compared to placebo in patients treated with either conventional or moderate ...

Russia's EnteroMix vaccine, based on mRNA tech, showed 100% efficacy in early cancer trials. Designed to shrink tumours and ...

Researchers developed FaceAge, an AI tool that calculate's a patient biological age from a photo of their face. In a new study, the researchers tied FaceAge results to health outcomes in people with ...